Financhill
Sell
33

EDAP Quote, Financials, Valuation and Earnings

Last price:
$2.33
Seasonality move :
-1.53%
Day range:
$2.24 - $2.39
52-week range:
$2.00 - $8.50
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.24x
P/B ratio:
1.78x
Volume:
4.3K
Avg. volume:
35.9K
1-year change:
-69.47%
Market cap:
$85M
Revenue:
$65.4M
EPS (TTM):
-$0.63

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
EDAP
Edap TMS SA
$20.8M -$0.11 -1.4% -21.79% $10.67
AKTX
Akari Therapeutics PLC
-- -- -- -- --
BDRX
Biodexa Pharmaceuticals PLC
-- -- -- -- $17.97
CLLS
Cellectis SA
$9.6M -$0.21 204.72% -100% $5.80
DBVT
DBV Technologies SA
$1.1M -$0.22 -- -59.89% $21.81
GNFT
Genfit SA
-- -- -- -- $10.17
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
EDAP
Edap TMS SA
$2.29 $10.67 $85M -- $0.00 0% 1.24x
AKTX
Akari Therapeutics PLC
$1.10 -- $27.2M -- $0.00 0% --
BDRX
Biodexa Pharmaceuticals PLC
$2.12 $17.97 $1.4M -- $0.00 0% 1.91x
CLLS
Cellectis SA
$1.23 $5.80 $122.6M -- $0.00 0% 2.90x
DBVT
DBV Technologies SA
$4.68 $21.81 $96M -- $0.00 0% --
GNFT
Genfit SA
$3.64 $10.17 $181.7M 32.57x $0.00 0% 2.64x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
EDAP
Edap TMS SA
8.17% -1.273 4.48% 1.42x
AKTX
Akari Therapeutics PLC
-- 0.585 -- --
BDRX
Biodexa Pharmaceuticals PLC
-- 0.756 -- 1.20x
CLLS
Cellectis SA
27.15% 1.831 27.1% 1.70x
DBVT
DBV Technologies SA
-- -0.036 -- --
GNFT
Genfit SA
-- 0.867 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
EDAP
Edap TMS SA
$5.7M -$6.4M -39.29% -42.5% -44.53% -$6.7M
AKTX
Akari Therapeutics PLC
-- -$1.9M -- -- -- -$1.5M
BDRX
Biodexa Pharmaceuticals PLC
-- -- -160.77% -160.77% -- --
CLLS
Cellectis SA
-- -$10.7M -22.9% -31.46% 65.62% -$1.8M
DBVT
DBV Technologies SA
-- -$30.3M -- -- -- -$22.9M
GNFT
Genfit SA
-- -- -- -- -- --

Edap TMS SA vs. Competitors

  • Which has Higher Returns EDAP or AKTX?

    Akari Therapeutics PLC has a net margin of -48.85% compared to Edap TMS SA's net margin of --. Edap TMS SA's return on equity of -42.5% beat Akari Therapeutics PLC's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    EDAP
    Edap TMS SA
    39.35% -$0.19 $51.9M
    AKTX
    Akari Therapeutics PLC
    -- -$0.24 --
  • What do Analysts Say About EDAP or AKTX?

    Edap TMS SA has a consensus price target of $10.67, signalling upside risk potential of 365.79%. On the other hand Akari Therapeutics PLC has an analysts' consensus of -- which suggests that it could grow by 7172.73%. Given that Akari Therapeutics PLC has higher upside potential than Edap TMS SA, analysts believe Akari Therapeutics PLC is more attractive than Edap TMS SA.

    Company Buy Ratings Hold Ratings Sell Ratings
    EDAP
    Edap TMS SA
    1 0 0
    AKTX
    Akari Therapeutics PLC
    0 0 0
  • Is EDAP or AKTX More Risky?

    Edap TMS SA has a beta of 0.372, which suggesting that the stock is 62.782% less volatile than S&P 500. In comparison Akari Therapeutics PLC has a beta of 0.895, suggesting its less volatile than the S&P 500 by 10.528%.

  • Which is a Better Dividend Stock EDAP or AKTX?

    Edap TMS SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Akari Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edap TMS SA pays -- of its earnings as a dividend. Akari Therapeutics PLC pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios EDAP or AKTX?

    Edap TMS SA quarterly revenues are $14.4M, which are larger than Akari Therapeutics PLC quarterly revenues of --. Edap TMS SA's net income of -$7M is lower than Akari Therapeutics PLC's net income of -$2.9M. Notably, Edap TMS SA's price-to-earnings ratio is -- while Akari Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edap TMS SA is 1.24x versus -- for Akari Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    EDAP
    Edap TMS SA
    1.24x -- $14.4M -$7M
    AKTX
    Akari Therapeutics PLC
    -- -- -- -$2.9M
  • Which has Higher Returns EDAP or BDRX?

    Biodexa Pharmaceuticals PLC has a net margin of -48.85% compared to Edap TMS SA's net margin of --. Edap TMS SA's return on equity of -42.5% beat Biodexa Pharmaceuticals PLC's return on equity of -160.77%.

    Company Gross Margin Earnings Per Share Invested Capital
    EDAP
    Edap TMS SA
    39.35% -$0.19 $51.9M
    BDRX
    Biodexa Pharmaceuticals PLC
    -- -- $6M
  • What do Analysts Say About EDAP or BDRX?

    Edap TMS SA has a consensus price target of $10.67, signalling upside risk potential of 365.79%. On the other hand Biodexa Pharmaceuticals PLC has an analysts' consensus of $17.97 which suggests that it could grow by 753.38%. Given that Biodexa Pharmaceuticals PLC has higher upside potential than Edap TMS SA, analysts believe Biodexa Pharmaceuticals PLC is more attractive than Edap TMS SA.

    Company Buy Ratings Hold Ratings Sell Ratings
    EDAP
    Edap TMS SA
    1 0 0
    BDRX
    Biodexa Pharmaceuticals PLC
    1 0 0
  • Is EDAP or BDRX More Risky?

    Edap TMS SA has a beta of 0.372, which suggesting that the stock is 62.782% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals PLC has a beta of 1.489, suggesting its more volatile than the S&P 500 by 48.943%.

  • Which is a Better Dividend Stock EDAP or BDRX?

    Edap TMS SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edap TMS SA pays -- of its earnings as a dividend. Biodexa Pharmaceuticals PLC pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios EDAP or BDRX?

    Edap TMS SA quarterly revenues are $14.4M, which are larger than Biodexa Pharmaceuticals PLC quarterly revenues of --. Edap TMS SA's net income of -$7M is higher than Biodexa Pharmaceuticals PLC's net income of --. Notably, Edap TMS SA's price-to-earnings ratio is -- while Biodexa Pharmaceuticals PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edap TMS SA is 1.24x versus 1.91x for Biodexa Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    EDAP
    Edap TMS SA
    1.24x -- $14.4M -$7M
    BDRX
    Biodexa Pharmaceuticals PLC
    1.91x -- -- --
  • Which has Higher Returns EDAP or CLLS?

    Cellectis SA has a net margin of -48.85% compared to Edap TMS SA's net margin of 46.57%. Edap TMS SA's return on equity of -42.5% beat Cellectis SA's return on equity of -31.46%.

    Company Gross Margin Earnings Per Share Invested Capital
    EDAP
    Edap TMS SA
    39.35% -$0.19 $51.9M
    CLLS
    Cellectis SA
    -- $0.08 $179.9M
  • What do Analysts Say About EDAP or CLLS?

    Edap TMS SA has a consensus price target of $10.67, signalling upside risk potential of 365.79%. On the other hand Cellectis SA has an analysts' consensus of $5.80 which suggests that it could grow by 373.47%. Given that Cellectis SA has higher upside potential than Edap TMS SA, analysts believe Cellectis SA is more attractive than Edap TMS SA.

    Company Buy Ratings Hold Ratings Sell Ratings
    EDAP
    Edap TMS SA
    1 0 0
    CLLS
    Cellectis SA
    2 1 0
  • Is EDAP or CLLS More Risky?

    Edap TMS SA has a beta of 0.372, which suggesting that the stock is 62.782% less volatile than S&P 500. In comparison Cellectis SA has a beta of 3.275, suggesting its more volatile than the S&P 500 by 227.454%.

  • Which is a Better Dividend Stock EDAP or CLLS?

    Edap TMS SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cellectis SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edap TMS SA pays -- of its earnings as a dividend. Cellectis SA pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios EDAP or CLLS?

    Edap TMS SA quarterly revenues are $14.4M, which are larger than Cellectis SA quarterly revenues of $12.7M. Edap TMS SA's net income of -$7M is lower than Cellectis SA's net income of $5.9M. Notably, Edap TMS SA's price-to-earnings ratio is -- while Cellectis SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edap TMS SA is 1.24x versus 2.90x for Cellectis SA. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    EDAP
    Edap TMS SA
    1.24x -- $14.4M -$7M
    CLLS
    Cellectis SA
    2.90x -- $12.7M $5.9M
  • Which has Higher Returns EDAP or DBVT?

    DBV Technologies SA has a net margin of -48.85% compared to Edap TMS SA's net margin of --. Edap TMS SA's return on equity of -42.5% beat DBV Technologies SA's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    EDAP
    Edap TMS SA
    39.35% -$0.19 $51.9M
    DBVT
    DBV Technologies SA
    -- -$1.60 --
  • What do Analysts Say About EDAP or DBVT?

    Edap TMS SA has a consensus price target of $10.67, signalling upside risk potential of 365.79%. On the other hand DBV Technologies SA has an analysts' consensus of $21.81 which suggests that it could grow by 366.09%. Given that DBV Technologies SA has higher upside potential than Edap TMS SA, analysts believe DBV Technologies SA is more attractive than Edap TMS SA.

    Company Buy Ratings Hold Ratings Sell Ratings
    EDAP
    Edap TMS SA
    1 0 0
    DBVT
    DBV Technologies SA
    0 0 0
  • Is EDAP or DBVT More Risky?

    Edap TMS SA has a beta of 0.372, which suggesting that the stock is 62.782% less volatile than S&P 500. In comparison DBV Technologies SA has a beta of 0.707, suggesting its less volatile than the S&P 500 by 29.271%.

  • Which is a Better Dividend Stock EDAP or DBVT?

    Edap TMS SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edap TMS SA pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios EDAP or DBVT?

    Edap TMS SA quarterly revenues are $14.4M, which are larger than DBV Technologies SA quarterly revenues of --. Edap TMS SA's net income of -$7M is higher than DBV Technologies SA's net income of -$30.4M. Notably, Edap TMS SA's price-to-earnings ratio is -- while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edap TMS SA is 1.24x versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    EDAP
    Edap TMS SA
    1.24x -- $14.4M -$7M
    DBVT
    DBV Technologies SA
    -- -- -- -$30.4M
  • Which has Higher Returns EDAP or GNFT?

    Genfit SA has a net margin of -48.85% compared to Edap TMS SA's net margin of --. Edap TMS SA's return on equity of -42.5% beat Genfit SA's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    EDAP
    Edap TMS SA
    39.35% -$0.19 $51.9M
    GNFT
    Genfit SA
    -- -- --
  • What do Analysts Say About EDAP or GNFT?

    Edap TMS SA has a consensus price target of $10.67, signalling upside risk potential of 365.79%. On the other hand Genfit SA has an analysts' consensus of $10.17 which suggests that it could grow by 189.3%. Given that Edap TMS SA has higher upside potential than Genfit SA, analysts believe Edap TMS SA is more attractive than Genfit SA.

    Company Buy Ratings Hold Ratings Sell Ratings
    EDAP
    Edap TMS SA
    1 0 0
    GNFT
    Genfit SA
    1 0 0
  • Is EDAP or GNFT More Risky?

    Edap TMS SA has a beta of 0.372, which suggesting that the stock is 62.782% less volatile than S&P 500. In comparison Genfit SA has a beta of 1.135, suggesting its more volatile than the S&P 500 by 13.542%.

  • Which is a Better Dividend Stock EDAP or GNFT?

    Edap TMS SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Genfit SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Edap TMS SA pays -- of its earnings as a dividend. Genfit SA pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios EDAP or GNFT?

    Edap TMS SA quarterly revenues are $14.4M, which are larger than Genfit SA quarterly revenues of --. Edap TMS SA's net income of -$7M is higher than Genfit SA's net income of --. Notably, Edap TMS SA's price-to-earnings ratio is -- while Genfit SA's PE ratio is 32.57x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Edap TMS SA is 1.24x versus 2.64x for Genfit SA. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    EDAP
    Edap TMS SA
    1.24x -- $14.4M -$7M
    GNFT
    Genfit SA
    2.64x 32.57x -- --

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is the Market Going to Go Lower?
Is the Market Going to Go Lower?

The last month has been extremely difficult for the stock…

2 Dividend Stocks to Buy in a Recession
2 Dividend Stocks to Buy in a Recession

While many economists and investors initially expected 2025 to be…

Is Ford Stock Undervalued Amid the EV Transition?
Is Ford Stock Undervalued Amid the EV Transition?

There is a lot going on in the electric vehicle…

Stock Ideas

Buy
53
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
54
Is NVDA Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 41x

Buy
51
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Alerts

Buy
52
RGC alert for Mar 18

Regencell Bioscience Holdings [RGC] is up 73.51% over the past day.

Buy
63
EXOD alert for Mar 18

Exodus Movement [EXOD] is down 3.96% over the past day.

Sell
45
MNPR alert for Mar 18

Monopar Therapeutics [MNPR] is up 0.93% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock